Compositions and methods for efficient production of myo-inositol from glucose in a two-stage fermentation process
The two-stage fermentation process enhances myo-inositol production in E. coli by using genetically modified strains with improved glucose uptake and metabolic control, achieving high yields and rates.
Patent Information
- Application Number
- PCT/US2026/026463
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-04
- Publication Date
- 2026-11-12
AI Technical Summary
Existing biotechnology-based fermentation processes for producing myo-inositol are inefficient, resulting in low yields and production rates.
A two-stage fermentation process utilizing genetically modified E. coli strains with enhanced glucose uptake systems and synthetic metabolic valves, combined with conditional gene expression and proteolysis, to produce myo-inositol at high yields and rates.
The process achieves a yield of -160 g/L of myo-inositol in -68 h with an overall glucose yield of over 70%, significantly improving production efficiency.
Smart Images

Figure US2026026463_12112026_PF_FP_ABST
Abstract
Description
Atty Docket: 49186-00182COMPOSITIONS AND METHODS FOR EFFICIENT PRODUCTION OF MYOINOSITOL FROM GLUCOSE IN A TWO-STAGE FERMENTATION PROCESS CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 800,165, filed May 5, 2025, which application is incorporated herein by reference in its entirety.REFERENCE TO A SEQUENCE LISTING
[0002] The instant application contains a Sequence Listing which has been filed electronically in st26 format and is hereby incorporated by reference in its entirety was created on May 3, 2025, is named 49186-00166.xml and is 46,782 bytes in size.BACKGROUND OF THE INVENTION
[0003] Biotechnology -based fermentation processes have been developed to produce everything from biologies and small molecule therapies to specialty, bulk and commodity chemicals.
[0004] Inositol is a form of sugar your body naturally produces to provide structure to your cells. It can also be found in certain foods, including meat, fruits, com, beans, grains and legumes. The typical American diet contains 1 gram of inositol a day. But research suggests that taking an inositol supplement may have many health benefits. Research has shown inositol may provide many important functions. In addition to playing a role in the development of cell membranes, inositol may also have an effect on insulin and certain chemical messengers in the brain.SUMMARY OF THE INVENTION
[0005] The present disclosure provides for the production of myo-inositol from glucose, for example, in E. coll via 2-stage fermentation. Strains are described capable of producing -160 g / L of myo-inositol in a -68 h fermentation, with an overall yield in glucose over 70%.BRIEF DESCRIPTION OF THE DRAWINGS
[0006] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative aspects, in which the principles of the invention are utilized, and the accompanying drawings of which:-1- 25967882 vlAtty Docket: 49186-00182
[0007] Fig. 1 depicts a comparison of myo-inositol production between PTS and non-PTS strains with 2-stage microfermentation. Fermentations were performed using engineered mutants following the standard protocol with a production OD of 4. Samples were collected at 24 hours post-inoculation. Bar plots represent myo-inositol-specific production, while scatter plots indicate post-production optical density (OD). Data are presented as mean values + / - 1 SD.
[0008] Fig. 2 depicts myo-inositol microfermentation results of PTS strains with different metabolic valves. The base strain of the mutants is PTS strain HS001717 (Control).Microfermentation of the mutants was carried out follow ing the standard protocol with a production OD of 4. Samples were collected at 24 hours post-inoculation. Bar plots represent myo-inositol-specific production, while scatter plots indicate post-production optical density (OD). Data are presented as mean values + / - 1 SD.
[0009] Fig. 3 depicts 3 myo-inositol microfermentation results for IPS ortholog screening. The fermentation of the mutants was carried out following 2-stage microfermentation protocol with a production OD of 1. All pathw ay plasmids were derived from the control plasmid PID001233 pSMART-phoAp-EcIMP-IN-yibDp-ScIPS by replacing the ScIPS gene with various IPS orthologs. Samples were collected at 24 hours post-inoculation. Bar plots represent myo-inositol-specific production, while scatter plots indicate post-production optical density (OD). Data are presented as mean values + / - 1 SD.
[0010] Fig. 4 depicts myo-inositol microfermentation results for pathway architecture optimization. The fermentation of the mutants was carried out following 2-stage microfermentation protocol with a production OD of 1. Samples were collected and measured at 24 h post-inoculation. Bar plots represent myo-inositol-specific production, while the scatter plots denote the post-production OD. Data are presented as mean values + / - 1 SD.
[0011] Fig. 5A-5B: depicts RBS sequences for the construction of the plasmid pools
[0012] Fig. 6A-6C depicts microfermentation results for the pathway library screening. The fermentation of the mutants was carried out following 2-stage microfermentation protocol with a production OD of 1. Samples were collected and measured at 24 h post-inoculation. Strain PS002518, containing plasmid PID001653, served as a reference control. The bar plots represent the myo-inositol-specific production, while the scatter plots denote the postproduction OD.
[0013] Fig. 7 depicts Fed-batch bioreactor fermentation of results of production strain LIB000007.026.-2- 25967882 vlAtty Docket: 49186-00182
[0014] Fig. 8 depicts Fed-batch bioreactor fermentation of results of production strain PS003387. Data are presented as mean values + / - 1 SD.DETAILED DESCRIPTION OF THE INVENTIONDefinitions
[0015] As used in the specification and the claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an "expression vector” includes a single expression vector as well as a plurality of expression vectors, either the same (e.g., the same operon) or different; reference to “microorganism” includes a single microorganism as well as a plurality of microorganisms; and the like.
[0016] As used herein, “reduced enzymatic activity,” “reducing enzymatic activity,” and the like is meant to indicate that a microorganism cell, or an isolated enzyme, exhibits a lower level of activity than that measured in a comparable cell of the same species or its native enzyme. That is, enzy matic conversion of the indicated substrate(s) to indicated product(s) under known standard conditions for that enzyme is at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, or at least 90 percent less than the enzymatic activity' for the same biochemical conversion by a native (non-modified) enzyme under a standard specified condition. This term also can include elimination of that enzy matic activity. A cell having reduced enzymatic activity of an enzyme can be identified using any method known in the art. For example, enzyme activity assays can be used to identify cells having reduced enzyme activity. See, for example. Enzyme Nomenclature, Academic Press, Inc., New York 2007.
[0017] The term “heterologous DNA,” “heterologous nucleic acid sequence,” and the like as used herein refers to a nucleic acid sequence wherein at least one of the following is true: (a) the sequence of nucleic acids foreign to (i.e., not naturally found in) a given host microorganism; (b) the sequence may be naturally found in a given host microorganism, but in an unnatural (e.g., greater than expected) amount; or (c) the sequence of nucleic acids comprises two or more subsequences that are not found in the same relationship to each other in nature. For example, regarding instance (c), a heterologous nucleic acid sequence that is recombinantly produced will have two or more sequences from unrelated genes arranged to make a new functional nucleic acid, such as a normative promoter driving gene expression.-3- 25967882 vlAtty Docket: 49186-00182
[0018] The term “synthetic metabolic valve,” and the like as used herein refers to either the use of controlled proteolysis, gene silencing or the combination of both proteolysis and gene silencing to alter metabolic fluxes.
[0019] The term “heterologous” is intended to include the term "exogenous" as the latter term is generally used in the art. Within the scientific community “heterologous gene” is generally understood as “derived from a different organism. With reference to the host microorganism's genome prior to the introduction of a heterologous nucleic acid sequence, the nucleic acid sequence that codes for the enzyme is heterologous (whether or not the heterologous nucleic acid sequence is introduced into that genome).
[0020] As used herein, the term “gene disruption,” or grammatical equivalents thereof (and including "to disrupt enzymatic function," "disruption of enzymatic function." and the like), is intended to mean a genetic modification to a microorganism that renders the encoded gene product as having a reduced polypeptide activity compared with polypeptide activity in or from a microorganism cell not so modified. The genetic modification can be, for example, deletion of the entire gene, deletion or other modification of a regulatory sequence required for transcription or translation, deletion of a portion of the gene which results in a truncated gene product (e.g., enzyme) or by any of various mutation strategies that reduces activity7(including reducing activities to no detectable activity level) the encoded gene product. A disruption may broadly include a deletion of all or part of the nucleic acid sequence encoding the enzyme, and also includes, but is not limited to other types of genetic modifications, e.g., introduction of stop codons, frame shift mutations, introduction or removal of portions of the gene, and introduction of a degradation signal, those genetic modifications affecting mRNA transcription levels and / or stability , and altering the promoter or repressor upstream of the gene encoding the enzyme.
[0021] Bio-production or fermentation, as used herein, may be aerobic, rmcroaerobic, or anaerobic.
[0022] When the genetic modification of a gene product, e.g., an enzyme, is referred to herein, including the claims, it is understood that the genetic modification is of a nucleic acid sequence, such as or including the gene, that normally encodes the stated gene product, e.g., the enzyme.
[0023] As used herein, the term “metabolic flux” and the like refers to changes in metabolism that lead to changes in product and / or byproduct formation, including production rates, production titers and production yields from a given substrate.-4- 25967882 vlAtty Docket: 49186-00182
[0024] Species and other phylogenic identifications are according to the classification known to a person skilled in the art of microbiology’.
[0025] Enzymes are listed here within, with reference to a Universal Protein Resource (Uniprot) identification number, which would be well known to one skilled in the art (Uniprot is maintained by and available through the UniProt Consortium).
[0026] The term “homolog” can be defined as follows. Genes that have a common evolutionary origin are considered homologous. This means they share a significant sequence similarity, often because they were derived from a single ancestral gene. Genes encoding the same protein in two different species are often homologous. The term "homolog" can be used to describe genes, proteins, structures, or even entire chromosomes. Homology is not just about superficial similarities, but about shared evolutionaryhistory. Genes from organisms of different species that code for the same enzyme or otherpr oduct. Homologous genes need not have the same base sequences. An ortholog is a gene in one species that shares a common ancestor with a gene in another species, and the two genes have diverged due to a speciation event (splitting of a species into two or more distinct lineages). Orthologs are a type of homologous gene, meaning they share a common ancestor. Orthologs are always found in different species, unlike paralogs, which are duplicated within the same species. Orthologs often retain the same or similar function as their ancestral gene, although mutations and other evolutionary changes can lead to functional divergence.
[0027] Myo-inositol, PubChem CID 892, with a molecular formula CeHnOe and molecular weight of 180.16 g / mol is also referred to by the following synonyms: 6917-35-7, Myoinositol, mesoinositol, Inosite, Insitolum, Isoinositol, Inositol, ID-myo-Inositol, dOmyo-inositol, IL-myo-Inositol, l,2,3,5-trans-4,6-Cyclohexanehexol, cis-, Inositol, myo, 1.2.3.4.5.6-HEXAHYDROXY-CYCLOHEXANE, (lr,2R,3S,4s,5R,6S)-cyclohexane- 1.2.3.4.5.6-hexol, (lR,2S,3r,4R,5S,6s)-cyclohexane-l,2,3,4,5,6-hexol, inositols, Inositol [Nonspecific isomer], INOSITOL, MESO, orthorhombic myo-inositol, cyclohexane- lR.2R,3S,4S,5R.6S-hexol. I,2,3,5trans4,6cyclohexanehexol, chiro inositol, cisl,2,3,5trans4,6cyclohexanehexol, Scyllo-inositol, epi-Inositol, Muco-InositoL Alloinositol, i-Inositol, Neo-inositol, IL-Chiro-inositol, Quercinitol, Cocositol, Meat sugar, Myoinosite, Dambose, chiro-inositol, Inositene, Inositina, Phaseomannite, Inosital, Inositol, myo-, Iso-inositol, L-chiro-Inositol, Cyclohexitol, Cyclohexanehexol, (-)-Inositol, Inositol, allo-. Inositol, muco-, Inositol, scyllo-, alloinositol, neoinositol. Hexahydroxy cyclohexane,-5- 25967882 vlAtty Docket: 49186-00182scyllo-Cyclohexanehexol, (lR,2R,3S,4S,5S,6S)-Cyclohexane-l,2,3,4,5,6-hexaol, epi-Cyclohexanehexol, (-)-chiro-Inositol, (+)-Chiro-Inositol, (lR.2S,3r,4R.5S,6r)-cyclohexane-1,2,3,4,5,6-hexol ,(lR,2S,3s,4R,5S,6s)-cyclohexane-l,2,3,4,5,6-hexol.
[0028] Where methods and steps described herein indicate certain events occurring in certain order, those of ordinary' skill in the art will recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of the invention. Additionally, certain steps may be performed concurrently in a parallel process when possible, as well as performed sequentially.
[0029] The meaning of abbreviations is as follows: “C” means Celsius or degrees Celsius, as is clear from its usage, DCW means dry cell weight, "s" means second(s), “min’' means minute(s), “h,” “hr,” or "hrs” means hour(s), “psi” means pounds per square inch, “nm” means nanometers, “d” means day(s), “pL” or “uL” or “ul” means microliter(s), “mL” means milliliter(s), “L” means liter(s), “mm” means millimeter(s), “nm” means nanometers, “mM” means millimolar, “pM” or “uM” means micromolar, “M” means molar, “mmol” means millimole(s), “pmol” or “uMol” means micromole(s). “g” means gram(s), “pg” or “ug” means microgram(s) and “ng” means nanogram(s), "PCR” means polymerase chain reaction, “OD” means optical density, “ODeoo” means the optical density measured at a photon wavelength of 600 nm, “kDa” means kilodaltons, “g” means the gravitation constant, “bp” means base pair(s), “kbp” means kilobase pair(s), “% w / v” means weight / volume percent, “% v / v” means volume / volume percent. “IPTG” means isopropyl-p-D-thiogalactopyranoiside, “aTc” means anhydrotetracycline, “RBS” means ribosome binding site, “rpm” means revolutions per minute, “HPLC” means high performance liquid chromatography, and “GC” means gas chromatography, “NCBI” refers to the national Center for Biotechnology Information, “IPS” refers to any gene encoding a inositol phosphate synthase or any enzyme that catalyzes the following chemical reaction: D-glucose 6-phosphate ID-myo-inositol 3-phosphate; “IMP” refers to any gene encoding a inositol monophosphatase or any enzy me that catalyzed the following chemical reaction: myo-inositol phosphate + H2O myo-inositol + phosphate; “PTS” refers to any phosphoenolpyruvate: sugar phosphotransferase system; “SMV” refers to synthetic metabolic valve; “G6P” refers to glucose-6-phospate; “glk”, “Glk” and “GLK” all refer to glucose kinase; “MF” refers to microfermentation; “EcIMP” is short hand referring the IMP gene or enzy me of E. coli. Likewise, “TmIMP” is short hand for the IMP gene or enzyme of Thermotoga maritima and ScIPS is short hand for the IMP gene or enzyme of S'. cerevisiae (all of these orthologs are fully defined in Table 3).-6- 25967882 vlAtty Docket: 49186-00182Throughout the specification a gene name may be accompanied by a term in parenthesis following the gene name that represents a specific example of such gene. For example, the term “enoyl-ACP reductase (fabl) gene" encompasses any enoyl-ACP reductase gene, whether that be a homolog, ortholog or paralog of the exemplary E. coli gene noted in parenthesis. That is, the exemplary7E. coli gene fabl noted in parenthesis is just an example of the genus of genes encompassed by “enoyl-ACP reductase gene”.Overview
[0030] The present disclosure provides for the production of myo-inositol from glucose in E. coli via2-stage fermentation. We have designed, constructed, and tested A. coli strains capable of producing -160 g / L of myo-inositol in a -68 h fermentation, with an overall yield in glucose over 70% (over 85% in the production phase) in a 2-stage fed-batch fermentation.
[0031] The invention regards to strains that combines the following elements: modifications to the mechanism for glucose uptake. Some strains use the phosphoenol pyruvate: sugar phosphotransferase system (PTS). Other strains have mutations that inactivate the PTS system and overexpress genes or include mutations that boost alternative glucose uptake systems (non-PTS). Alternatively, the strains may overexpress genes or include mutations that boost alternative glucose uptake systems while the PTS system is also active.
[0032] Another element of modification is that the strains carry one or several Synthetic Metabolic Valves (SMVs), including valves targeting phosphoglucose isomerase, glucose-6-phosphate-1 -dehydrogenase, a soluble transhydrogenase or pyridine nucleotide transhydrogenase, a lipoamide dehydrogenase, a pyruvate kinase, glyceraldehyde phosphate dehydrogenase, enoyl-ACP reductase, a isocitrate dehydrogenase, dihydrolipoamide aetyltransferase, a glucose dehydrogenase, a ribulose-phosphate 3-epimerase, and citrate synthase.
[0033] Yet another element of modification is the conditional overexpression of the genes synthesizing Inositol phosphate from glucose-6-phosphate (IPS), and inositol (myo-inositol) from inositol phosphatase (IMP). Different promoters, RBS, and IPS and IMP orthologs and mutants have been tested.
[0034] Yet another element of modification is that other genes such as a glucokinase, or glk, may have been also overexpressed.
[0035] In one aspect, the invention, what is fully described is a genetically modified microorganism with a production pathway comprising at least one enzyme for producing a -7- 25967882 vlAtty Docket: 49186-00182product from a glucose-6-phosphate precursor. The microorganism with this production pathway, when placed under conditions of depletion or partial depletion of a limiting nutrient from a growth medium in which the genetically modified microorganism is growing, will be inducted into a stationary phase or non-dividing cellular state. During this stationary phase, glucose-6-phosphate isomerase, glucose-6-phosphate 1 -dehydrogenase, or glucose dehydrogenase enzyme activities are eliminated or reduced, with the next effect being, during the stationary phase a glucose-6-phosphate pool for optimal product production. The microorganism may also be modified so that sugar uptake is enhanced when comparing to the genetically modified microorganism to a non-genetically modified microorganism from which the genetically modified microorganism is derived.
[0036] In one aspect of the invention, the genetically modified microorganism effective for producing a product from a glucose-6-phosphate precursor will be modified such that the glucose-6-phosphate isomerase is the pgi gene and this gene will be conditionally reduced in gene expression or enzyme activity' during a stationary' phase.
[0037] In one aspect of the invention, the genetically modified microorganism effective for producing a product from a glucose-6-phosphate precursor will be modified such that the glucose-6-phosphate 1 -dehydrogenase gene is the zwf gene and this gene will be conditionally reduced in gene expression or enzyme activity' during a stationary' phase.
[0038] In one aspect of the invention, the genetically modified microorganism effective for producing a product from a glucose-6-phosphate precursor will be modified such that the glucose dehydrogenase gene is the gdh gene and this gene will be conditionally reduced in gene expression or enzyme activity' during a stationary' phase described above.
[0039] In one aspect of the invention, the genetically modified microorganism, capable of producing a product from a glucose-6-phosphate precursor, produces the product myoinositol and the production pathway comprises enzymes having inositol-phosphate synthase (IPS) or inositol monophosphatase (IMP) activities.
[0040] In one aspect of the invention, the genetically modified microorganism, the microorganism further regulates the expression of the udhA gene or enzyme because adding such regulation modifies the redox balance of the cell which is required required for a proper function of the IPS enzyme, the enzyme that converts G6P into Inositol-mono-phosphate
[0041] In one aspect of the invention, the genetically modified microorganism produces the product myo-inositol and the production pathway comprise an enzyme having inositolphosphate synthase (IPS) activity and encoded by an IPS gene of Saccharomyces cerevisiae.-8- 25967882 vlAtty Docket: 49186-00182or an IPS gene of Oryzct sativa, or an IPS gene of Arabidopsis thaliana, an IPS gene of Citrus paradisi, an IPS gene of Dictyostelium discoideum, an IPS gene of Populus euphratica, an IPS gene of Triticum aestivum, an IPS gene of Thermococcus pact ficus. an IPS gene of Thermochaetoides thermophila DSM 1495, an IPS gene of Zea mays, an IPS gene of Gossypium hirsutum, or a homolog or ortholog thereof.
[0042] In one aspect of the invention, the genetically modified microorganism produces the product myo-inositol and the production pathway comprise an enzyme having inositol monophosphatase (IMP) activity is encoded by an IMP gene of Escherichia coli or an IMP gene of Thermotoga maritima, or a homolog or ortholog thereof.
[0043] In one aspect of the invention, the genetically modified microorganism is further characterized by a conditionally triggered synthetic metabolic valve that silences gene expression or a conditionally triggered synthetic metabolic valve that enables selective proteolysis, wherein the synthetic metabolic valve is conditional triggered during the stationary phase or non-dividing cellular state. In one aspect of the invention, the genetically modified microorganism comprises a synthetic metabolic valve that silences gene expression is directed to silencing a enoyl-ACP reductase (fabl) gene, a citrate synthase (gltA) gene, a soluble transhydrogenase or pyridine nucleotide transhydrogenase (udhA) gene, a glucose-6-phosphate-1 -dehydrogenase (zwf) gene, a lipoamide dehydrogenase (Ipd) gene, a glucose-6-phosphate isomerase (pgi) gene, a glucose dehydrogenase (gdh) gene, a pyruvate kinase (pykF or pykA) gene, a ribulose-phosphate 3-epimerase (rpe) gene, a isocitrate dehydrogenase (icd) gene or a combination thereof, or the synthetic metabolic valve that enables selective proteolysis is directed to silencing a enoyl-ACP reductase (fabl) enzy me, a citrate synthase (gltA) enzyme, a soluble transhydrogenase (udhA) enzy me, a glucose-6-phosphate-l-dehydrogenase (zwf) enzyme , a lipoamide dehydrogenase (Ipd) enzyme, a glucose-6-phosphate isomerase (pgi) enzyme, a glucose dehydrogenase (gdh) enzyme, a pyruvate kinase (pykF or pykA) enzyme, a ribulose-phosphate 3-epimerase (rpe) enzyme, a isocitrate dehydrogenase (icd) enzy me or a combination thereof.
[0044] In one aspect of the invention, the genetically modified microorganism is a bacteria or a yeast. In another aspect of the invention, the genetically modified microorganism is E. coli or S. cerevisiae.
[0045] In one aspect of the invention, the genetically modified microorganism is further characterized in that the increased sugar uptake is achieved by including a mutation or deletion of a gene of the phosphotransferase system (PTS) system.-9- 25967882 vlAtty Docket: 49186-00182
[0046] In one aspect of the invention, the genetically modified microorganism is further characterized in that the increased sugar uptake is achieved by including the activation of the native non-PTS glucose utilization pathway.
[0047] In one aspect of the invention, the genetically modified microorganism is further characterized in that the activity of a repressor of the galactose operon (galR) is reduced.
[0048] In one aspect of the invention, the genetically modified microorganism is further characterized in that a repressor of the galactose operon (galR) is deleted or inactivated. In one aspect, the genetically modified microorganism is further characterized in that the increased sugar uptake is achieved by introducing a heterologous non-PTS glucose utilization pathway. In some aspects of the invention this heterologous non-PTS glucose utilization pathway may include a heterologous glucose facilitator (gif) or heterologous or native glucokinase (glk) gene is expressed to a level different that in the native microorganism. In some aspects of the invention this heterologous non-PTS glucose utilization pathway may include expression of a glucose facilitator (zglf) gene or a glucokinase (zglk) gene of Zym.om.onas mobilis, or a homolog thereof.
[0049] In one aspect of the invention, the invention compnses a genetically modified microorganism, where the growth of the microorganism and production of a product both occur without the addition of second sugar or alcohol other than glucose.Synthetic metabolic valves (SMVs)
[0050] Synthetic metabolic valves (SMVs) comprise one or more or a combination of the following: controlled gene silencing and controlled proteolysis. It is appreciated that one well skilled in the art is aware of several methodologies for gene silencing and controlled proteolysis. The microbial strains disclosed herein are utilized in a multi-stage bioprocess encompassing as least two stages, the first stage in which microorganisms are grown, and metabolism can be optimized for microbial growth and at least one other stage in which growth can be slowed or stopped, and dynamic changes can be made to metabolism to improve production of desired product, such as myo-inositol. The transition of growing cultures between stages and the manipulation of metabolic fluxes can be controlled by artificial chemical inducers or preferably by controlling the level of key limiting nutrients. In addition, genetic modifications may be made to provide metabolic pathways for the biosynthesis of one or more chemical or fuel products. Also, genetic modifications may be made to enable the utilization of a variety of carbon feedstocks including but not limited-10- 25967882 vlAtty Docket: 49186-00182sugars such as glucose, sucrose, xylose, arabinose, mannose, and lactose, oils, carbon dioxide, carbon monoxide, methane, methanol and formaldehyde.
[0051] This approach allows for simpler models of metabolic fluxes and physiological demands during a production phase, turning a growing cell into a stationary phase biocatalyst. These synthetic metabolic valves can be used to turn off essential genes and redirect carbon, electrons and energy flux to product formation in a multi-stage fermentation process. One or more of the following enables these synthetic valves: 1) transcriptional gene silencing or repression technologies in combination with 2) inducible enzyme degradation and 3) nutrient limitation to induce a stationary or non-dividing cellular state. SMVs are generalizable to any pathway and microbial host. These synthetic metabolic valves allow for novel rapid metabolic engineering strategies useful for the production of renewable chemicals and fuels and any product that can be produced via whole cell catalysis.
[0052] In various cases, one SMV can refer to the manipulation of one gene (or its protein product). The manipulation can be controlled silencing of the gene and / or controlled degradation of its protein product. In certain cases, combination of SMVs can lead to improved production in yields, rate and / or robustness, which includes manipulation of two genes (or their protein products). In some cases, an engineered microorganism comprises at least one SMV. In some cases, an engineered microorganism comprises more than one SMV. In some cases, an engineered microorganism comprises two, three, four, five, six, seven, eight, nine, or ten, or more SMVs.Gene Silencing
[0053] In particular the invention describes the use of controlled gene silencing to help enable the control over metabolic fluxes in controlled multi-stage fermentation processes. There are several methodologies known in the art for controlled gene silencing, including but not limited to mRNA silencing or RNA interference, silencing via transcriptional repressors and CRISPR interference.
[0054] In some cases, a valve polynucleotide comprises a silencing polynucleotide, and said silencing polynucleotide comprises a guide RNA (gRNA) comprising a gRNA sequence that recognizes a promoter of a gene encoding said valve enzyme.
[0055] In some cases, a valve polynucleotide further encodes a CRISPR enzy me, wherein said CRISPR enzyme specifically binds to said promoter sequence when bound to said gRNA. In some cases, a CRISPR enzyme is catalytically inactive.-11- 25967882 vlAtty Docket: 49186-00182
[0056] In some cases, a valve polynucleotide comprises a degradation polynucleotide, wherein said degradation polynucleotide comprises a sequence encoding a degradation tag, wherein said degradation tag mediates degradation of said valve enzyme. In some cases, the expression of a valve polynucleotide is regulated by phosphate availability in a cell.Controlled Proteolysis
[0057] In particular the current disclosure describes the use of controlled protein degradation or proteolysis to help enable the control over metabolic fluxes in controlled multi-stage fermentation processes. There are several methodologies known in the art for controlled protein degradation, including but not limited to targeted protein cleavage by a specific protease and controlled targeting of proteins for degradation by specific peptide tags. Systems for the use of the E. coll clpXP protease for controlled protein degradation can be used. This methodology relies upon adding a specific C-terminal peptide tag such as a DAS4 (or DAS+4) tag. Proteins with this tag are not degraded by the clpXP protease until the specificity7enhancing chaperone sspB is expressed. sspB induces degradation of DAS4 tagged proteins by the clpXP protease. In additional numerous site-specific protease systems are well known in the art. Proteins can be engineered to contain a specific target site of a given protease and then cleaved after the controlled expression of the protease. In some aspects the cleavage can be expected lead to protein inactivation or degradation. For example, an N-terminal sequence can be added to a protein of interest to enable clpS dependent clpAP degradation. In addition, this sequence can further be masked by an additional N-terminal sequence, which can be controllable cleaved such as by a ULP hydrolase. This allows for controlled N-rule degradation dependent on hydrolase expression. It is therefore possible to tag proteins for controlled proteolysis either at the N-terminus or C-terminus.
[0058] The preference of using an N-terminal vs. C-terminal tag will largely depend on whether either tag affects protein function prior to the controlled onset of degradation. The invention describes the use of controlled protein degradation or proteolysis to help enable the control over metabolic fluxes in controlled multi-stage fermentation processes, in E. coli. There are several methodologies known in the art for controlled protein degradation in other microbial hosts, including a wide range of gram-negative as well as gram-positive bacteria, yeast and even archaea. In particular, systems for controlled proteolysis can be transferred from a native microbial host and used in a non-native host.Synthetic Metabolic Valve Control-12- 25967882 vlAtty Docket: 49186-00182
[0059] In particular the current disclosure describes the use of synthetic metabolic valves to control metabolic fluxes in multi-stage fermentation processes. There are numerous methodologies known in the art to induce expression that can be used at the transition between stages in multistage fermentations. These include but are not limited to artificial chemical inducers including: tetracycline, anhydrotetracy cline, lactose, IPTG (isopropyl-beta-D-l-thiogalactopyranoside), arabinose, raffinose, tryptophan and numerous others. Systems linking the use of these well known inducers to the control of gene expression silencing and / or controlled proteolysis can be integrated into genetically modified microbial systems to control the transition between grow th and production phases in multi-stage fermentation processes.
[0060] In addition, it may be desirable to control the transition between growth and production in multi-stage fermentations by the depletion of one or more limiting nutrients that are consumed during growth. Limiting nutrients can include but are not limited to: phosphate, nitrogen, sulfur and magnesium. Natural gene expression systems that respond to these nutrient limitations can be used to operably link the control of gene expression silencing and / or controlled proteolysis to the transition between growth and production phases in multistage fermentation processes.Enzymes for Inositol production
[0061] According to some aspects of the invention, the desired product to be produced is myo-inositol. While exemplary genes and enzymes are described in the examples in some detail for use in producing myo-inositol in the genetically modified microorganisms and biofermentation processed described herein, it is appreciated that any enzy me that can conduct the step of D-glucose 6-phosphate to ID-myo-inositol 3-phosphate is encompassed by the instant invention as is any enzyme that can conduct the following process: myo-inositol phosphate to myo-inositol.Inositol phosphate synthase
[0062] As described above, “IPS” refers to any gene encoding a inositol phosphate synthase or any enzyme that catalyzes the following chemical reaction: D-glucose 6-phosphate ID-myo-inositol 3-phosphate. While numerous examples of useable IPS enzymes are described in the examples, it is appreciated that any homolog, ortholog, or paralog of any of the cited IPS genes or enzymes are also encompassed by the present invention. Including for example any nucleotide sequence that is 80 % identical to the entire portion of the nucleotide sequence identified in Table 3 (sequences available as of the filing date of this application) that -13- 25967882 vlAtty Docket: 49186-00182encodes an IMP enzyme as determined by BLAST sequence align tool searching standard databases with no exclusions and searching only for highly similar sequences. Even more preferably, a nucleotide sequence would be 90% or 95 % identical to the coding sequence of the gene described in Table 3 as determined as described above and still be encompassed by the invention. Similarly, the term IPS fairly encompasses any enzy me, even is that enzy me does is not named inositol phosphate synthase, that carries out a reaction: D-glucose 6-phosphate ID-myo-inositol 3-phosphate, with any appropriate cofactors.
[0063] Inositol monophosphatase
[0064] As described above, “IMP” refers to any gene encoding an inositol monophosphatase or any enzy me that catalyzed the following chemical reaction: myo-inositol phosphate + H2O mvo-inositol + phosphate. While numerous examples of useable IMP enzymes are described in the examples, it is appreciated that any homolog, ortholog, or paralog of any of the cited IMP genes or enzymes are also encompassed by the present invention. Including for example any nucleotide sequence that is 80 % identical to the entire portion of the nucleotide sequence identified in Table 3 (sequences available as of the filing date of this application) that encodes an IMP enzyme as determined by BLAST sequence align tool searching standard databases with no exclusions and searching only for highly similar sequences. Even more preferably, a nucleotide sequence would be 90% or 95 % identical to the coding sequence of the gene described in Table 3 as determined as described above and still be encompassed by the invention. Similarly, the term IMP fairly encompasses any enzyme, even is that enzy me does is not named inositol monophosphatase, that carries out a reaction: inositol monophosphatase. That is, a nonspecific monophosphatase may be substituted for IMP to practice the claimed invention.Inositol Derivatives
[0065] It is appreciated that according to some aspects of the invention, the desired product is not only myo-inostiol itself but a myo-inositol derivative. Therefore, the genetically modified microorganism of the present invention, and bio-fermentation methods that rely on the genetically modified microorganism may easily provide for large quantities of myoinositol which is itself the precursor for generating an inositol derivative. Such inositol derivatives may include an inositol stereoisomer such as D-c / izro-inositol, L-cAzro-inositol, zm / co-inositol, scy / Zo-inositol, 1,2,3,4,5,6-cyclohexanehexol, neo-inositol, a / / o-inositol, cis-inositol, epz-inositol. Such inositol derivatives may include methyl ethers derivatives of inositol including bomesitol. ononitol, sequotol. dombonitol, viscumitol, D-Pinitol,-14- 25967882 vlAtty Docket: 49186-00182Quebrachitol, Pinpollitol, Brahol. Such inositol derivatives may include glucoside derivatives such as ciceritol, fagopyritol, or phytic acid. Such inositol derivatives may include inositol ceramides, sphingolipids, archeditylinositol, glycosyl inositols, mannose inositols, galatcose inositols, galatosamine inositols, glycan inositols, or dicarboxylic acids such as glucaric acid.Method and Systems for Bio-productionCarbon Sources
[0066] Bio-production media, which is used in the present invention with recombinant microorganisms must contain suitable carbon sources or substrates for both grow th and production stages. Suitable substrates may include, but are not limited to glucose, sucrose, xylose, mannose, arabinose, oils, carbon dioxide, carbon monoxide, methane, methanol, formaldehyde and glycerol. It is contemplated that all of the above mentioned carbon substrates and mixtures thereof are suitable in the present invention as a carbon source(s). Microorganisms
[0067] Features as described and claimed herein may be provided in a microorganism selected from the listing herein, or another suitable microorganism, that also comprises one or more natural, introduced, or enhanced product bio-production pathways. Thus, in some aspects the microorganism(s) comprise an endogenous product production pathway (which may, in some such aspects, be enhanced), whereas in other aspects the microorganism does not comprise an endogenous product production pathway.
[0068] The examples describe specific modifications and evaluations to certain bacterial and fungal microorganisms. The scope of the invention is not meant to be limited to such species, but to be generally applicable to a wide range of suitable microorganisms.
[0069] Suitable host cells or host microorganisms for bio-production can be either prokaryotic or eukaryotic. Suitable host cells or host microorganisms can be bacteria such as Citrobacter, Enterobacter, Clostridium, Klebsiella, Aerobacter, Lactobacillus, Aspergillus, Saccharomyces, Schizosaccharomyces, Zygosaccharomyces, Pichia, Kluyveromyces, Candida, Hansenula. Debaryomyces, Mucor, Torulopsis, Methylobacter, Escherichia, Salmonella, Bacillus. Streptomyces , and Pseudomonas . In some aspects, a host cell or an engineered cell is E. coli. In some aspects, a host cell or an engineered cell is S. cerevisiae.
[0070] Environmental Conditions-15- 25967882 vlAtty Docket: 49186-00182
[0071] Environmental conditions can comprise medium and culture conditions.Environmental factors that may influence production can be temperature. pH, acidity, ethanol, sulfite, oxygenation, and availability of nutrients.
[0072] Bio-production Reactors and Systems
[0073] Fermentation systems utilizing methods and / or compositions according to the invention are also within the scope of the invention.
[0074] Any of the recombinant microorganisms as described and / or referred to herein may be introduced into an industrial bio-production system where the microorganisms convert a carbon source into a product in a commercially viable operation. The bio-production system includes the introduction of such a recombinant microorganism into a bioreactor vessel, with a carbon source substrate and bio-production media suitable for growing the recombinant microorganism, and maintaining the bio-production system within a suitable temperature range (and dissolved oxygen concentration range if the reaction is aerobic or microaerobic) for a suitable time to obtain a desired conversion of a portion of the substrate molecules to a selected chemical product. Bio-productions may be performed under aerobic, microaerobic, or anaerobic conditions, with or without agitation. Industrial bio-production systems and their operation are well-known to those skilled in the arts of chemical engineering and bioprocess engineering. The amount of a product produced in a bio-production media generally can be determined using a number of methods known in the art, for example, high performance liquid chromatography (HPLC), gas chromatography (GC). or GC / Mass Spectroscopy (MS).
[0075] Genetic Modifications, Nucleotide Sequences, and Amino Acid Sequences
[0076] Aspects of the present disclosure may result from introduction of an expression vector into a host microorganism, wherein the expression vector contains a nucleic acid sequence coding for an enzyme that is, or is not. normally found in a host microorganism.
[0077] The ability to genetically modify a host cell is essential for the production of any genetically modified (recombinant) microorganism. The mode of gene transfer technology may be by electroporation, conjugation, transduction, or natural transformation. A broad range of host conjugative plasmids and drug resistance markers are available. The cloning vectors are tailored to the host organisms based on the nature of antibiotic resistance markers that can function in that host. Also, as disclosed herein, a genetically modified (recombinant) microorganism may comprise modifications other than via plasmid introduction, including modifications to its genomic DNA.-16- 25967882 vlAtty Docket: 49186-00182
[0078] More generally, nucleic acid constructs can be prepared comprising an isolated polynucleotide encoding a polypeptide having enzyme activity operably linked to one or more (several) control sequences that direct the expression of the coding sequence in a microorganism, such as E. coll, under conditions compatible with the control sequences. The isolated polynucleotide may be manipulated to provide for expression of the polypeptide. Manipulation of the polynucleotide's sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotide sequences utilizing recombinant DNA methods are well established in the art.
[0079] The control sequence may be an appropriate promoter sequence, a nucleotide sequence that is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present disclosure. The promoter sequence may contain transcriptional control sequences that mediate the expression of the polypeptide. The promoter may be any nucleotide sequence that shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell. The techniques for modifying and utilizing recombinant DNA promoter sequences are well established in the art.
[0080] For various aspects of the invention the genetic manipulations may be described to include various genetic manipulations, including those directed to change regulation of, and therefore ultimate activity of, an enzyme or enzymatic activity of an enzyme identified in any of the respective pathways. Such genetic modifications may be directed to transcriptional, translational, and post-translational modifications that result in a change of enzyme activity and / or selectivity under selected and / or identified culture conditions and / or to provision of additional nucleic acid sequences such as to increase copy number and / or mutants of an enzyme related to product production. Specific methodologies and approaches to achieve such genetic modification are well known to one skilled in the art.
[0081] For all nucleic acid and amino acid sequences provided herein, it is appreciated that conservatively modified variants of these sequences are included, and are within the scope of the invention in its various aspects. Functionally equivalent nucleic acid and amino acid sequences (functional variants), which may include conservatively modified variants as well as more extensively varied sequences, which are well within the skill of the person of ordinary skill in the art, and microorganisms comprising these, also are within the scope of-17- 25967882 vlAtty Docket: 49186-00182various aspects of the invention, as are methods and systems comprising such sequences and / or microorganisms.
[0082] Accordingly, as described in various sections above, some compositions, methods and systems of the present disclosure comprise providing a genetically modified microorganism that comprises both a production pathway to make a myo-inositol from a central intermediate in combination with synthetic metabolic valves to redistribute flux.
[0083] Products
[0084] In some aspects, provided herein is a microorganism or a cell for producing a product. In some cases, the product comprises myo-inositol. In some cases, a rate of production of myo-inositol is at least 0.1 g / L / hr, 0.2 g / L / hr, 0.3 g / L / hr, 0.4 g / L / hr, 0.5 g / L / hr, 0.6 g / L / hr, 0.7 g / L / hr, 0.8 g / L / hr, 0.9 g / L / hr, 1.0 g / L / hr, 1.1 g / L / hr. 1.2 g / L / hr, 1.3 g / L / hr, 1.4 g / L / hr, 1.5 g / L / hr, 1.6 g / L / hr, 1.7 g / L / hr, 1.8 g / L / hr, 1.9 g / L / hr, 2.0 g / L / hr, 2.5 g / L / hr, 3.0 g / L / hr, 3.5 g / L / hr, 4.0 g / L / hr, 4.5 g / L / hr, 5.0 g / L / hr, 5.5 g / L / hr, 6.0 g / L / hr, 7.0 g / L / hr, 8.0 g / L / hr, 9.0 g / L / hr, or at least 10 g / L / hr. In some cases, said culturing occurs for less than 20 hours, 30 hours, 40 hours, 50 hours, 60 hours, 70 hours, 80 hours. 90 hours, or less than 100 hours. In some cases, said culturing occurs for less than 80 hours. However typical yeast fermentation processes run much longer and are not so limited. For example, fermentation may occur for 100 hours or more.
[0085] Methods
[0086] Provided herein are methods for producing a product in an engineered microorganism in a large scale. Also provided herein are methods for engineering microorganisms for large-scale production of a product in a high-throughput fashion. In some aspects, a culture medium comprising said selected strain has a volume of at least 100 ml, 200 ml, 300 ml, 400 ml, 500 ml, 600 ml, 700 ml, 800 ml. 900 ml, or at least 1000 ml. In some aspects, a culture medium has a volume of at least IL.
[0087] In some aspects, a rate of production of the product during said stationary phase is reduced less in response to a change of an environmental condition as compared to a cell lacking said controlled reduction of expression of said valve enzyme.
[0088] Examples
[0089] Example 1: Host strain selection: Production of myo-inositol in 2-stage microfermentation in base PTS and Non-PTS strains with basic valves and myo-inositol synthesis pathways.25967882 vlAtty Docket: 49186-00182
[0090] E. coli has been widely employed for myo-inositol synthesis due to its rapid grow th and high enzyme expression levels. Glucose is transported into the cell and converted into the precursor glucose-6-phosphate (G6P), which is subsequently transformed into myo-inositol-l(or 3)-phosphate by myo-inositol- 1 (or 3)-phosphate synthase (IPS), and then into myoinositol by inositol monophosphatase (IMP). The conversion of glucose to G6P is a key step in the biosynthesis of myo-inositol. In previous studies, both phosphotransferase system (PTS) and non-PTS glucose utilization pathways have been explored for this purpose (Y ou et al., 2020; Tang et al., 2019), with their respective advantages and disadvantages summarized in Table 1.
[0091] Table 1 Comparison of myo-inositol synthesis with PTS or Non-PTS glucose utilization pathways:PTS Non-PTSGenes ptsGHI, err Zmglf zglk galP, glk mglBCA, glk Cofactor 1 PEP 1 ATP 1 ATP 2 ATP required (equivalent to 1 1 H+ATP) (>1.25 ATP)Theoretical 0.5 g / g glucose 1 g / g glucoseyield (If the glucose used for ATP supplementation is disregarded)Glucose to G6P 100% Based on the GLK enzyme efficiency
[0092] The PTS pathway is the primary route for glucose metabolism in E. coli. It not only supports cell growth but also directly supplies G6P for myo-inositol production. However, its theoretical yield is relatively low, at approximately 0.5 g of myo-inositol per gram of glucose. Additionally, the accumulation of pyruvate can hinder high-yield production. In contrast, the non-PTS pathway offers a higher theoretical yield — nearly 1 g of myo-inositol per gram of glucose. This pathway, however, depends on glucose kinase (GLK) activity’ for the conversion of glucose to G6P and typically results in higher ATP consumption, especially when using transport systems such as GalP / GLK or MglBAC / GLK.
[0093] Firstly, evaluation of myo-inositol production in host strains — both PTS and non-PTS — using basic metabolic valves and pathway plasmids was evaluated. Two-stage microfermentation (MF) was employed to identify the most promising strain for further -19- 25967882 vlAtty Docket: 49186-00182development. Detailed information on the host strains, metabolic valves, and plasmids used in this study is summarized in Table 2.
[0094] Table 2 Information on strains and pathways for the initial myo-inositol synthesis with host strainsHost Genomic PTS or non- MI synthesis pathwaystrains modifications PTS glucoseutilizationpathwayHS001717 Base strain PTS PID001233(pSMART-phoAp-EcIMP-yibDp- OsIPS)HS002026 HS001717, zwf- PTS PID001233das4HS002011 HS001717, pgi- PTS PID001233das4HS002158 HS001717, zwf- PTS PID001233das4. pgi-das4HS001960 Base strain Non-PTS PID001233HS001988 HS001960, zwf- Non-PTS PID001233das4HS001996 HS001960, pgi- Non-PTS PID001233das4HS001997 HS001960, pgi- Non-PTS PID001233das4. zwf-das4
[0095] The PTS strain HS001717 was selected as the base strain for the initial evaluation of myo-inositol production. PTS strain HS001717 was further engineered with deletions in multiple byproduct synthesis pathways, including those for acetate, ethanol, lactate, and formate, making it a suitable host strain for targeted product synthesis. The pgi and zwf genes play key roles in G6P metabolism. Downregulation or complete inactivation of these genes -20- 25967882 vlAtty Docket: 49186-00182can lead to the accumulation of G6P, thereby enhancing the production of myo-inositol . As such, metabolic valves targeting pgi, zwf, and the combination pgi / zwf were also assessed.
[0096] To support the two-stage fermentation process, the ScIPS gene from Saccharomyces cerevisiae and EcIMP from E. coli were expressed under the control of phosphate-inducible promoters yibDp and phoAp, respectively . Plasmid PID001233 was introduced into the PTS host strains (Table 2), and two-stage microfermentation experiments were subsequently carried out (Fig. 1). Results showed that the zwf metabolic valve positively influenced myoinositol production, while pgi had minimal effect. Notably, strains with both pgi and zwf valves achieved the highest myo-inositol titers among all PTS strains tested (Fig. 1).
[0097] The non-PTS strain HS001960 was selected as the base strain for the initial evaluation of myo-inositol fermentation. Similar to HS001717. HS001960 carries deletions in several byproduct synthesis pathways, including those for acetate, ethanol, lactate, and formate. To block the native PTS-mediated glucose utilization, the ptsG gene was replaced with a constitutively expressed glk gene from E. coli. Additionally, the promoter of galP gene was replaced with a constitutive promoter in the chromosome to further enhance glucose uptake via the non-PTS pathway. As in the PTS strain experiments, metabolic valves targeting pgi, zwf, and pgi / zwf were evaluated. The same pathway plasmid, PID001233, was introduced into non-PTS host strains (Table 2), and two-stage microfermentation was conducted (Fig. 1). In the non-PTS background, pgi and zwf individually had negligible effects on myo-inositol production, while their combination led to improved titers — consistent with observations in the PTS strains.
[0098] Given its significantly higher myo-inositol production in microfermentation compared to the non-PTS strain, the PTS strain HS002158 was selected as the lead strain for development of the myo-inositol synthesis.
[0099] Example 2: Screen of metabolic valves beneficial for myo-inositol synthesis
[0100] Previous results indicated that PTS strains are more suitable hosts for myo-inositol production. The impact of metabolic valves on myo-inositol synthesis in a PTS background was assessed by transformation with the pathway plasmid PID001233 into several HS001717-derived mutants. In these mutants, a das4 degradation tag was introduced into selected target genes, including pgi, zwf, udhA, Ipd, pykF, pykA, gapA, fabl, icd, aceF, gdh, rpe, and gltA. The parental HS001717 strain served as a control. As shown in Fig. 2, three of the metabolic valves (zwf / pgi, udhA, and zwf) led to a significant increase in myo-inositol specific production compared to the control strain.-21- 25967882 vlAtty Docket: 49186-00182
[0101] These beneficial valves were subsequently tested in various combinations. Among them, the engineered host strain HS002191, containing metabolic valves of pgi, zwf. and udhA, achieved the highest production level of -160 mg / L OD — in microfermentation.
[0102] Example 3: Screening of IPS and IMP orthologs for enhanced myo-inositol production
[0103] The activities of IPS and IMP enzymes play a critical role in determining the efficiency of myo-inositol synthesis. To further enhance production, we conducted a series of experiments aimed at screening orthologs of IPS and IMP to identify the most effective variants for myo-inositol biosynthesis.
[0104] IPS orthologs:
[0105] IPS has been identified as a key bottleneck in achieving high-yield myo-inositol production (You et al., 2020). To address this limitation, 15 new IPS orthologs were selected and evaluated (Table 3). For consistent comparison, each ortholog was expressed under the same yibDp promoter and ribosome binding site (RBS), and 15 corresponding plasmids were constructed. These plasmids were individually transformed into the host strain, and two-stage microfermentation was performed to assess and compare the performance of the IPS variants.
[0106] Table 3: 3 IPS and IMP orthologsIPS ProteinOrganism NCBI orthologs sizeScIPS Saccharomyces cerevisiae 533 aa NP_012382 OsIPS Oryza sativa 510 aa NP 001389012Variant (M147T) derived OslPS-1 Oryza sativa 510 aafrom OsIPS Vanant (M147T+M344Y) OsIPS-2 Oryza sativa 510 aaderived from OsIPS Variant (T154K+S192T) OSIPS-3 Oryza sativa 510 aaderived from OsIPS AtIPSI Arabidopsis thaliana 511 aa NP_195690-22- 25967882 vlAtty Docket: 49186-00182AtIPS2 Arabidopsis thaliana 510 aa NPJ79812 AtIPS3 Arabidopsis thaliana 510 aa NP_196579 CpIPS Citrus paradisi 507 aa CAA83565.1DdIPS Dictyostelium discoideum 511 aa XP 638094.1PelPSl Populus euphratica 510 aa XP_011030959.1 TalPS Triticum aestivum 510 aa AAD26330.1TpIPS Thermococcus paciflcus 382 aa ASJ05853.1Thermochaetoides thermophilaTtIPS 552 aa EGS18645.1DSM 1495ZmIPS Zea mays 510 aa AAC15756.1 GhIPS Gossypium hirsutum 510 aa XP 04094561I.I IMP ProteinOrganism NCBI orthologs sizeEcIMP Escherichia coli 268 aa WP_203369140.1TmIMP Thermotoga maritima 256 aa WP_004081652.1
[0107] Among the 15 IPS orthologs tested, TalPS, PelPS, GhIPS, and OsIPS-3 demonstrated improved myo-inositol production compared to the control ScIPS (Fig. 3). Notably, the strain expressing TalPS achieved more than a three-fold increase in specific myo-inositol production relative to the control, highlighting its strong potential for pathway optimization. Since the performance of enzymes in the fermentation depends on the context of the gene in the pathway, all top 3 variants were selected for rounds of optimization.
[0108] IMP orthologs:
[0109] Due to the generally high activity of IMP enzymes, only two orthologs — E. coli IMP (EcIMP) and Thermotoga maritima IMP (TmIMP) — were evaluated in this study (Table 3, Table 4, and Fig. 4). Microfermentation results indicated that the native E. coli EcIMP -23- 25967882 vlAtty Docket: 49186-00182outperformed the heterologous TmIMP. Based on these findings, EcIMP was selected as the fixed IMP ortholog for constructing all subsequent pathway plasmids.
[0110] Example 4: Optimization of myo-inositol biosynthetic pathway architecture
[0111] In the pathway design, IPS and IMP enzy mes are expressed under two separate phosphate-inducible promoters, phoAp and yibDp. However, this configuration has resulted in inconsistent gene expression and reduced plasmid stability. To address these issues, four alternative pathway architectures were constructed using OsIPS and EcIMP as the enzyme pair. The designs, summarized in Table 4, feature variations in promoter usage and gene positioning. We either expressed the two enzy mes under different promoters or under a single promoter with altered gene order, to evaluate their impact on expression stability and myoinositol production.
[0112] Table 4: Architectures of the myo-inositol synthesis pathwayPathway ID StructurePID001653 phoAp-EcIMP-yibDp-OsIPS-3 PID001928 phoAp-OsIPS-3-yibDp-EcIMP PID001657 phoAp-TmIMP-yibDp-OsIPS-3 PID001929 phoAp-OsIPS-3-yibDp-TmIMP PID001868 yibDp-EcIMP-OsIPS-3PID001930 yibDp-OsIPS-3-EcIMP
[0113] The plasmids were transformed into the host strain HS002191 to create new production strains. Two-stage microfermentation was performed to assess the impact of different pathway structures on myo-inositol synthesis. The results revealed that the pathway featuring the IPS-IMP operon controlled by a single yibDp promoter was the most efficient configuration for optimizing myo-inositol production. Myo-inositol production increased by more than two-fold in the strain harboring plasmid PID001930 compared to the control strain with plasmid PID001653 at 24 hours of fermentation.
[0114] Example 5: Optimization of IPS-IMP operon
[0115] The myo-inositol synthesis pathway involves the production of inositol-1 (or 3)-phosphate, an intermediate generated by IPS. The accumulation of inositol-1 (or 3)-phosphate can inhibit cell growth and reduce myo-inositol production. Proper expression of IPS and IMP is essential to prevent the buildup of this intermediate and mitigate the potential toxicity'-24- 25967882 vlAtty Docket: 49186-00182associated with sugar phosphates. To optimize this process, we constructed three pathway¬ plasmid pools, each containing one of three IPS variants (TalPS, PelPS, and GhIPS) and EcIMP (Fig. 5A-5B). The IPS-IMP operon was regulated by the yibDp promoter, with a range of ribosome binding site (RBS) strengths selected to screen for optimal expression levels of IPS and IMP. The library sizes of the three plasmid pools were 192, 144, and 144, respectively.
[0116] The plasmid pools were transformed into the host strain HS002191, and myo-inositol production was assessed through 2-stage microfermentation. The production strain PS002518 (HS002191, PID001653) was used as the control for all pathway screenings.Microfermentation results, shown in Fig. 6A-6C, revealed that the majority of the strains produced more myo-inositol than the control PS002518 strain. Several strains achieved production exceeding 1 g / L OD, which represents a four-fold increase compared to the control. The top-performing strains were selected for validation in bioreactor fermentation.
[0117] Example 6: Bioreactor validation of the top strain
[0118] Several production strains from the pathway screening were selected for validation in bioreactor fermentation. The top-performing strain, LIB000007.026, produced 47 g / L of myo-inositol after 64 hours of fed-batch fermentation. The myo-inositol productivity7and yield reached 0.73 g / L h and 0.59 g / g glucose, respectively. See Fig. 7
[0119] Example 7: Enhancing myo-inositol productivity and yield through engineering of glucose utilization pathwaysTo further enhance the yield and productivity of myo-inositol synthesis, we focused on engineering the glucose utilization pathways of the strain. Specifically: 1) To improve the glucose uptake rate and myo-inositol production yield, we deleted the galR gene, which inhibits galP expression; 2) We introduced a heterologous, non-PTS glucose utilization pathway from Zymomonas mobilis (zglf and zglk) into the strain to further boost glucose uptake and myo-inositol production; 3) To mitigate the potential toxicity of zglk overexpression during the grow th phase, we placed the zglk gene under the control of the yibDp phosphate-inducible promoter, ensuring the pathway is active only during the production phase. The new host strain HS002290 was built with reconstructed glucose utilization pathways. The optimal pathw ay plasmid w as then transformed into the host strain HS002290, resulting in the production strain PS003387. Bioreactor fermentation of this strain yielded approximately 160 g / L of myo-inositol over 68 hours, with a productivity- of 2.32 g / L h and a yield of 0.73 g / g glucose, see Fig. 8. In addition to the high myo-inositol -25- 25967882 vlAtty Docket: 49186-00182production, strain PS003387 demonstrated enhanced stability during bioreactor fermentation, even after several rounds of subculture.
[0120] While preferred aspects of the present invention have been show n and described herein, it will be obvious to those skilled in the art that such aspects are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the aspects of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.25967882 vl
Claims
Atty Docket: 49186-00182CLAIMS1. A genetically modified microorganism comprising:a production pathway comprising at least one enzy me for producing a product from a glucose-6-phosphate precursor,wherein, under conditions of depleting of a limiting nutrient from a grow th medium in which the genetically modified microorganism is growing, a stationary phase or non-dividing cellular state is induced,wherein glucose-6-phosphate isomerase, glucose-6-phosphate 1-dehydrogenase, glucose dehydrogenase, or pyridine nucleotide transhydrogenase enzyme activities are reduced within the genetically modified microorganism to result in a glucose-6-phosphate pool; andwherein sugar uptake is enhanced within the genetically7modified microorganism, when compared to a non-genetically modified microorganism.
2. The genetically modified microorganism of claim 1, wherein the glucose-6-phosphate isomerase is the pgi gene.
3. The genetically modified microorganism of claim 1, wherein the glucose-6-phosphate 1 -dehydrogenase gene is the zwf gene.
4. The genetically modified microorganism of claim 1 , w herein the glucose dehydrogenase is the gdh gene.
5. The genetically modified microorganism of claim 1, w herein the pyridine nucleotide transhydrogenase gene is the udhA gene.-27- 25967882 vlAtty Docket: 49186-001826. The genetically modified microorganism of claim 1 , wherein product from a glucose-6-phosphate precursor is myo-inositol and the production pathway comprises enzymes having inositol-phosphate synthase (IPS) or inositol monophosphatase (IMP) activities.
7. The genetically modified microorganism of claim 1, wherein product from a glucose-6-phosphate precursor is an inositol derivative.
8. The genetically modified microorganism of claim 5, wherein inositolphosphate synthase (IPS) enzy me is an IPS gene of Saccharomyces cerevisiae, or an IPS gene of Oryza sativa, or an IPS gene of Arabidopsis thaliana, an IPS gene of Citrus paradisi, an IPS gene of Dictyostelium discoideum, an IPS gene of Populus euphratica, an IPS gene of Triticum aestivum, an IPS gene of Thermococcus pacificus, an IPS gene of Thermochaetoides thermophila DSM 1495, an IPS gene of Zea mays, an IPS gene of Gossypium hirsutum, or a homolog or ortholog thereof.
9. The genetically modified microorganism of claim 5, wherein inositol monophosphatase (IMP) is an IMP gene of Escherichia coli or an IMP gene of Thermotoga maritima, or a homolog or ortholog thereof.
10. The genetically modified microorganism of claim 1 further comprising a conditionally triggered synthetic metabolic valve that silences gene expression or a conditionally triggered synthetic metabolic valve that enables selective proteolysis, wherein the synthetic metabolic valve is conditional triggered during the stationary phase or nondividing cellular state.-28- 25967882 vlAtty Docket: 49186-0018211. The genetically modified microorganism of claim 9, wherein the synthetic metabolic valve that silences gene expression is directed to silencing a enoyl-ACP reductase (fabl) gene, a citrate synthase (gltA) gene, a soluble transhydrogenase (udhA) gene, a glucose-6-phosphate-l-dehydrogenase (zwf) gene, a lipoamide dehydrogenase (Ipd) gene, a glucose-6-phosphate isomerase (pgi) gene, a glucose dehydrogenase (gdh) gene, a pyruvate kinase (pykF or pykA) gene, a ribulose-phosphate 3-epimerase (rpe) gene, a isocitrate dehydrogenase (icd) gene or a combination thereof, orthe synthetic metabolic valve that enables selective proteolysis is directed to silencing a enoyl-ACP reductase (fabl) enzy me, a citrate synthase (gltA) enz me, a soluble transhydrogenase (udhA) enzy me, a glucose-6-phosphate-l -dehydrogenase (zwf) enzy me , a lipoamide dehydrogenase (Ipd) enzy me, a glucose-6-phosphate isomerase (pgi) enzyme, a glucose dehydrogenase (gdh) enzy me, a pyruvate kinase (pykF or pykA) enzyme, a ribulosephosphate 3-epimerase (rpe) enzyme, a isocitrate dehydrogenase (icd) enzy me or a combination thereof.
12. The genetically modified microorganism of claim 1. wherein the microorganism is a bacteria or a yeast.
13. The genetically modified microorganism of claim 1, wherein the microorganism is E. coli or S. cerevisiae.
14. The genetically modified microorganism of claim 1, wherein the increased sugar uptake is achieved by including a mutation or deletion of a gene of the phosphotransferase system (PTS) system.-29- 25967882 vlAtty Docket: 49186-0018215. The genetically modified microorganism of claim 1, wherein the increased sugar uptake is achieved by including the activation of the native non-PTS glucose utilization pathway.
16. The genetically modified microorganism of claim 14, wherein the activity of a repressor of the galactose operon (galR) is reduced.
17. The genetically modified microorganism of claim 14, wherein a repressor of the galactose operon (galR) is deleted or inactivated.
18. The genetically modified microorganism of claim 1, wherein the increased sugar uptake is achieved by introducing a heterologous non-PTS glucose utilization pathway.
19. The genetically modified microorganism of claim 17, wherein a heterologous glucose facilitator (gif) or heterologous or native glucokinase (glk) gene is expressed to a level different that in the native microorganism.
20. The genetically modified microorganism of claim 18, wherein a glucose facilitator (zglf) gene or a glucokinase (zglk) gene of Zymomonas mobilis, or a homolog thereof is expressed.
21. The genetically modified microorganism of claim 1. wherein growth of the microorganism and production of a product both occur without the addition of second sugar or alcohol other than glucose.
22. The genetically modified microorganism of claim 1, wherein glucose-6-phosphate isomerase, glucose-6-phosphate 1 -dehydrogenase, glucose dehydrogenase, or pyridine nucleotide transhydrogenase enzyme activities are reduced by regulation of the gene-30- 25967882 vlAtty Docket: 49186-00182by a synthetic metabolic valve or by deletion of modification of a chromosomal copy of the gene.25967882 vl
